To use PEDs or not to use PEDs: a cost benefit analysis with math and everything

Leave a comment

Catherine Rampell of the New York Times’ “Economix” blog has a post up attempting to quantify the cost-benefit analysis that goes into a baseball player’s choice to use PEDs
or not and speculates about how the system can be re-jiggered so as to
further disincentivize drug use. Anyone who has thought about this
stuff for any length of time is aware of the general arguments even if
they haven’t done any of the actual math, but it’s probably worth a
read anyway. The best quote, though, is an aside about the assumptions
that go into her equations:

Now these numbers are obviously all made up (and no one gets signed
to $10 million deals off the street, I imagine). And players surely
care about things other than their paycheck — love of the game, fans,
Cooperstown, etc.

That sound you hear is Scott Boras firing off an angry letter to the
New York Times’ editor telling him just how wrong Ms. Rampell is about
all of those things.

Jeff Samardzija to undergo MRI on right shoulder

Denis Poroy/Getty Images

Update (12:58 AM ET): Per Henry Schulman of the San Francisco Chronicle, Samardzija has been diagnosed with a strained pectoral muscle. He’ll be shut down for a week. That’s good news for the Giants, considering the alternatives.


Giants starter Jeff Samardzija will undergo an MRI on his ailing right shoulder, according to NBC Sports Bay Area. The right-hander struggled in a minor league game on Wednesday, surrendering a pair of home runs and hitting a batter. Overall this spring, Samardzija has given up 15 runs (13 earned) on 17 hits (six homers) and seven walks with seven strikeouts in 11 innings.

This may mean Samardzija won’t be ready for the start of the regular season. Derek Holland would likely replace Samardzija in the rotation. Holland had been competing for the No. 5 spot in the Giants’ rotation.

Samardzija led the National League in losses last season with 15, also posting a 4.42 ERA with a 205/32 K/BB ratio in a league-high 207 2/3 innings. Since becoming a starter, Samardzija has been able to avoid injury, making 32 or 33 starts in each of the last five seasons.